A prospective study was conducted by van Dartel et al. over a duration of five years to follow up patients with anti-TNF-alpha and observe the risk of infection by using the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry focusing on comparisons of patients starting one of the three anti-TNF-alpha inhibitor (etanercept, infliximab, adalimumab) [36]. The gene discussed is TNF; the disease is rheumatoid arthritis.